EGFR and neoplasm: In our previous study, clinically, JX-594 demonstrated tumor selectivity via viral thymidine kinase (vTK) inactivation because cancer cells have high cellular TK levels due to Epidermal growth factor receptor (EGFR) pathway activation, in which the VV was evolved to replicate selectively in tumors.